Nektar Therapeutics (NKTR) News Today $0.93 -0.02 (-2.58%) Closing price 04:00 PM EasternExtended Trading$0.97 +0.04 (+3.84%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Nektar Therapeutics chief legal officer sells shares worth $11,150February 21 at 6:34 PM | investing.comNektar Therapeutics officer sells shares worth over $10,000February 21 at 6:34 PM | investing.comB.Riley Financial Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)February 17, 2025 | markets.businessinsider.comNektar Therapeutics (NASDAQ:NKTR) Short Interest Up 22.0% in JanuaryNektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 5,760,000 shares, a growth of 22.0% from the January 15th total of 4,720,000 shares. Approximately 3.2% of the shares of the company are short sold. Based on an average daily volume of 1,930,000 shares, the days-to-cover ratio is currently 3.0 days.February 16, 2025 | marketbeat.comSamlyn Capital, LLC Increases Stake in Nektar TherapeuticsFebruary 14, 2025 | gurufocus.comEventide Asset Management, LLC Reduces Stake in Nektar TherapeuticsFebruary 14, 2025 | gurufocus.comDeep Track Capital, LP Reduces Stake in Nektar TherapeuticsFebruary 14, 2025 | gurufocus.comPeapod Lane Capital LLC Makes New $1.03 Million Investment in Nektar Therapeutics (NASDAQ:NKTR)Peapod Lane Capital LLC bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 1,107,516 shares of the biopharmaceutical company's stock, valued at approximately $1,030,000. PeapFebruary 13, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Recommendation of "Moderate Buy" from AnalystsFebruary 13, 2025 | americanbankingnews.comFDA grants Fast Track to Nektar's atopic dermatitis drugFebruary 10, 2025 | msn.comNektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of ...February 10, 2025 | gurufocus.comNektar receives FDA Fast Track Designation for rezpegaldesleukinFebruary 10, 2025 | markets.businessinsider.comNektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic DermatitisFebruary 10, 2025 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating andFebruary 8, 2025 | marketbeat.comNektar Therapeutics Sees Unusually High Options Volume (NASDAQ:NKTR)Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock investors acquired 7,673 call options on the company. This represents an increase of approximately 3,045% compared to the average volume of 244 call options.February 5, 2025 | marketbeat.comZacks Research Issues Optimistic Forecast for NKTR EarningsNektar Therapeutics (NASDAQ:NKTR - Free Report) - Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for Nektar Therapeutics in a note issued to investors on Wednesday, January 29th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earniFebruary 3, 2025 | marketbeat.comJPMorgan Chase & Co. Grows Position in Nektar Therapeutics (NASDAQ:NKTR)JPMorgan Chase & Co. boosted its stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 197.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 913,300 shares of the biopharmaceutical company's stock after buJanuary 25, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Recommendation of "Moderate Buy" from BrokeragesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, four have given a buy ratingJanuary 14, 2025 | marketbeat.comNektar Therapeutics: Promising Drug Pipeline and Strategic Expansion Drive Buy RatingJanuary 13, 2025 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Nektar Therapeutics (NASDAQ:NKTR)HC Wainwright reiterated a "buy" rating and issued a $6.50 price objective on shares of Nektar Therapeutics in a research report on Monday.January 13, 2025 | marketbeat.comBuy Rating for Nektar Therapeutics: Promising Clinical Trial Strategy and Efficacy of RezpegJanuary 12, 2025 | markets.businessinsider.comNektar completes enrollment in REZOLVE-AD Phase 2b study of rezpegaldesleukinJanuary 10, 2025 | markets.businessinsider.comNektar Therapeutics (NKTR) Gets a Buy from Piper SandlerJanuary 10, 2025 | markets.businessinsider.comNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical ...January 10, 2025 | gurufocus.comNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic DermatitisJanuary 10, 2025 | prnewswire.comAnalysts Set Expectations for NKTR FY2024 EarningsNektar Therapeutics (NASDAQ:NKTR - Free Report) - Research analysts at B. Riley issued their FY2024 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, January 7th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical comJanuary 10, 2025 | marketbeat.comWhat is Zacks Research's Estimate for NKTR FY2024 Earnings?Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Zacks Research lifted their FY2024 EPS estimates for Nektar Therapeutics in a research report issued on Monday, January 6th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will earn ($0.76) per share for the year,January 9, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by B. RileyB. Riley upgraded shares of Nektar Therapeutics to a "strong-buy" rating in a research report on Tuesday.January 9, 2025 | marketbeat.comB. Riley Securities Initiates Coverage of Nektar Therapeutics (NKTR) with Buy RecommendationJanuary 8, 2025 | msn.comNektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at B. RileyB. Riley started coverage on Nektar Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $4.00 price objective on the stock.January 8, 2025 | marketbeat.comNektar initiated with a Buy at B. RileyJanuary 8, 2025 | markets.businessinsider.comNektar Therapeutics (NKTR) Gets a Buy from B.Riley FinancialJanuary 8, 2025 | markets.businessinsider.comInstitutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownershipJanuary 4, 2025 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Insider Sells $30,061.80 in StockDecember 27, 2024 | insidertrades.comNektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 33,402 SharesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Mark Andrew Wilson sold 33,402 shares of the company's stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the completion of the sale, the insider now owns 351,892 shares of the company's stock, valued at approximately $316,702.80. This represents a 8.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.December 26, 2024 | marketbeat.comNektar Therapeutics chief legal officer sells shares worth $44,800December 26, 2024 | investing.comJonathan Zalevsky Sells 51,115 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockDecember 21, 2024 | insidertrades.comNektar Therapeutics (NASDAQ:NKTR) Insider Sells $48,048.10 in StockNektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total value of $48,048.10. Following the sale, the insider now owns 326,904 shares of the company's stock, valued at approximately $307,289.76. This represents a 13.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.December 20, 2024 | marketbeat.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells 46,995 Shares of StockDecember 20, 2024 | insidertrades.comHoward W. Robin Sells 46,995 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockNektar Therapeutics (NASDAQ:NKTR - Get Free Report) CEO Howard W. Robin sold 46,995 shares of the firm's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the completion of the sale, the chief executive officer now owns 1,195,710 shares in the company, valued at $1,207,667.10. The trade was a 3.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.December 19, 2024 | marketbeat.comNektar Therapeutics CEO Robin Howard sells $131,649 in stockDecember 19, 2024 | investing.comPromising Future for Nektar Therapeutics: Innovative Approach in Autoimmune Disease Treatment with RezpegaldesleukinDecember 12, 2024 | markets.businessinsider.comResearch Analysts Issue Forecasts for NKTR FY2024 EarningsNektar Therapeutics (NASDAQ:NKTR - Free Report) - Analysts at HC Wainwright issued their FY2024 earnings per share estimates for Nektar Therapeutics in a report issued on Tuesday, December 10th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will post earnings of ($0.46)December 12, 2024 | marketbeat.comNektar initiated with a Buy at H.C. WainwrightDecember 11, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for NKTR Q1 Earnings?Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Nektar Therapeutics in a note issued to investors on Tuesday, December 10th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will posDecember 11, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Coverage Initiated by Analysts at HC WainwrightHC Wainwright started coverage on shares of Nektar Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $6.50 price objective on the stock.December 10, 2024 | marketbeat.comNektar's NKTR-255 After CD19 CAR-T Therapy Enhances Complete Response In R/R Large B-Cell LymphomaDecember 8, 2024 | markets.businessinsider.comNektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH MeetiDecember 7, 2024 | investing.comNektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH MeetingDecember 7, 2024 | prnewswire.comEventide Asset Management LLC Boosts Holdings in Nektar Therapeutics (NASDAQ:NKTR)Eventide Asset Management LLC boosted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 24.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 9,400,000 shares of the biopharmaceutical company's stock after purchasing an additioNovember 29, 2024 | marketbeat.com Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.640.60▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼23▲NKTR Articles Average Week Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OMER News Today ASMB News Today CPIX News Today LLY News Today JNJ News Today ABBV News Today MRK News Today PFE News Today BMY News Today ZTS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTR Stock Alerts